Find recruiting clinical trials for breast cancer in the UK � including triple negative (TNBC), HER2+, HR+, and metastatic subtypes. See your treatment pathway and where trials fit in.
Free to use � Live data from ClinicalTrials.gov � Updated hourly
Answer a few questions about your condition and we'll match you to the most relevant clinical trials.
See where clinical trials fit into your treatment journey
Treatment before or after surgery for early-stage disease
Standard: Chemotherapy, hormone therapy, HER2-targeted therapy, or combination
First treatment for advanced or metastatic breast cancer
Standard: Hormone therapy + CDK4/6 inhibitor (HR+) or Chemotherapy + HER2 therapy (HER2+)
After progression on 1st-line treatment
Standard: PI3K inhibitor, mTOR inhibitor, antibody-drug conjugate (Enhertu, Sacituzumab)
After multiple progressions � clinical trials are especially important
Standard: Clinical trial, further targeted therapy, or SAC
The most common subtype. Hormone receptor positive, HER2 negative. Treatments include hormone therapy, CDK4/6 inhibitors, and targeted therapies for specific mutations (ESR1, PIK3CA).
Overexpresses the HER2 protein. Treatments include trastuzumab, pertuzumab, T-DM1, and the newer antibody-drug conjugate Enhertu (trastuzumab deruxtecan).
Does not express estrogen, progesterone, or HER2 receptors. More aggressive but treatment is evolving rapidly with immunotherapy and antibody-drug conjugates like sacituzumab govitecan.
Loading trials from ClinicalTrials.gov...
Yes. Many trials specifically recruit patients who have completed surgery (adjuvant trials) to test treatments that reduce the risk of recurrence. Neoadjuvant trials before surgery are also common.
ADCs like Enhertu (trastuzumab deruxtecan) and Trodelvy (sacituzumab govitecan) deliver chemotherapy directly to cancer cells. They are transforming treatment for HER2+ and triple-negative breast cancer.
Yes. TNBC has many active trials investigating immunotherapy, PARP inhibitors (for BRCA carriers), antibody-drug conjugates, and novel targeted therapies. TNBC is a major research priority.
Many trials include comprehensive genetic testing as part of screening or treatment planning. This can identify BRCA and other mutations that may guide treatment choices for you and your family.
Use our search above to find trials that match your condition and location. Review the eligibility criteria carefully.
Talk to your GP or specialist about any trials you are interested in. They can help determine if a trial is appropriate for you.
Reach out to the trial team directly using the contact information on the ClinicalTrials.gov listing. They will guide you through screening.
If you meet the criteria and decide to participate, you will go through informed consent and begin the trial process.